ArticleOncology letters2020

Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma.

Zhaoyan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.